# Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

> **NCT06625320** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Revolution Medicines, Inc.** · enrollment: 500 (actual)

## Conditions studied

- Pancreatic Cancer
- PDAC
- PDAC - Pancreatic Ductal Adenocarcinoma

## Interventions

- **DRUG:** RMC-6236
- **DRUG:** Gemcitabine
- **DRUG:** nab-paclitaxel
- **DRUG:** Irinotecan
- **DRUG:** Liposomal irinotecan
- **DRUG:** 5-fluorouracil
- **DRUG:** leucovorin
- **DRUG:** Oxaliplatin

## Key facts

- **NCT ID:** NCT06625320
- **Lead sponsor:** Revolution Medicines, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-10-16
- **Primary completion:** 2026-06
- **Final completion:** 2027-12
- **Target enrollment:** 500 (ACTUAL)
- **Last updated:** 2026-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06625320

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06625320, "Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06625320. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*